arrow
K

Kuo-Chih Tseng

department of internal medicine
H指数:22
被引数:1,992

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

HBV RNA, HBcrAg, and HBsAg levels at year 6 do not predict HCC risk in patients with cirrhosis on long-term entecavir therapy

HBV RNA、HBcrAg和HBsAg水平在6年时不预测长期恩替卡韦治疗患者的肝硬化患者发生HCC的风险

2026-08-080
PRE
Survival impact of hepatitis C virus eradication in patients with or without active hepatocellular carcinoma: A nationwide cohort study

丙型肝炎病毒清除对伴有或不伴有活动性肝细胞癌患者的生存影响:一项全国性队列研究

2025-11-140
PRE
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan

Sofosbuvir/Velpatasvir治疗对2型糖尿病和慢性丙型肝炎患者肝外表现的影响: 来自台湾全国丙型肝炎病毒登记处的见解

2025-06-200
OAAI
Long-term risk of depression and the impact of risk factors among chronic hepatitis C patients after successful antiviral therapy: A nationwide real-world Taiwanese cohort (T-COACH)

慢性丙型肝炎患者抗病毒治疗成功后抑郁症的长期风险及风险因素的影响:一项全国性真实世界台湾队列研究(T-COACH)

2025-06-090
OAAI
Impact of Hepatitis C Virus Clearance on Cardiovascular Risk: A Real-World Experience From the Nationwide Taiwan Hepatitis C Virus Registry

丙型肝炎病毒清除对心血管风险的影响: 来自全国台湾丙型肝炎病毒登记处的真实经验

2025-05-240
OAAI
Posttreatment FIB-4 score change predicts hepatocellular carcinoma in chronic hepatitis C patients: Findings from the Taiwan hepatitis C registry program

治疗后FIB-4评分变化预测慢性丙型肝炎患者发生肝细胞癌:来自台湾丙型肝炎登记计划的研究结果

2025-02-280
OAAI
Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB
2024-12-010
PRE
Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy
2024-07-016
OAAI
An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan
2024-01-213
OAAI
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naive patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry
2023-03-278
OAAI
Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan
2023-02-0139
PRE
Sofosbuvir/velpatasvir/voxilaprevir for patients with chronic hepatitis C virus infection previously treated with NS5A direct-acting antivirals: a real-world multicenter cohort in Taiwan

Sofosbuvir/velpatasvir/voxilaprevir用于先前接受NS5A直接作用抗病毒药物治疗的慢性丙型肝炎病毒感染患者: 台湾真实世界的多中心队列

2023-01-2614
OA
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
2022-05-0123
PRE
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals
2022-02-074
OAAI